search
Back to results

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Dupilumab
placebo
ICS/LABA therapy
Salbutamol/albuterol
Levosalbutamol/levalbuterol
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

Participants with a physician diagnosis of moderate to severe, uncontrolled asthma for >=12 months, based on the Global Initiative for Asthma (GINA) 2009 Guidelines and:

  • Existing treatment with moderate or high-dose inhaled corticosteroid / long-acting beta-2 agonist
  • Forced expiratory volume (FEV1) 40 to 80% of predicted normal
  • Asthma Control Questionnaire, 5-question version (ACQ-5) score >=1.5
  • Reversibility of at least 12% and 200 mL in forced expiratory volume (FEV1)
  • Had experienced, within prior year: hospitalization, emergency or urgent care visit or systemic corticosteroid treatment for worsening asthma

Exclusion criteria:

  • Participants <18 years
  • Chronic obstructive pulmonary disease (COPD) or other lung diseases (eg, emphysema, idiopathic pulmonary fibrosis, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis) which impaired pulmonary function tests
  • Chest X-ray within 12 months of screening visit or at screening visit with clinically significant findings of lung disease(s) other than asthma
  • Current smoker or cessation of smoking within 6 months prior to Visit 1
  • Previous smoker with a smoking history >10 pack-years

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Sites / Locations

  • Investigational Site Number 840050
  • Investigational Site Number 840041
  • Investigational Site Number 840019
  • Investigational Site Number 840029
  • Investigational Site Number 840022
  • Investigational Site Number 840013
  • Investigational Site Number 840044
  • Investigational Site Number 840007
  • Investigational Site Number 840014
  • Investigational Site Number 840036
  • Investigational Site Number 840032
  • Investigational Site Number 840040
  • Investigational Site Number 840043
  • Investigational Site Number 840006
  • Investigational Site Number 840024
  • Investigational Site Number 840027
  • Investigational Site Number 840039
  • Investigational Site Number 840048
  • Investigational Site Number 840026
  • Investigational Site Number 840053
  • Investigational Site Number 840017
  • Investigational Site Number 840030
  • Investigational Site Number 840028
  • Investigational Site Number 840052
  • Investigational Site Number 840045
  • Investigational Site Number 840046
  • Investigational Site Number 840051
  • Investigational Site Number 840018
  • Investigational Site Number 840002
  • Investigational Site Number 840003
  • Investigational Site Number 840037
  • Investigational Site Number 840004
  • Investigational Site Number 840011
  • Investigational Site Number 840016
  • Investigational Site Number 840025
  • Investigational Site Number 840015
  • Investigational Site Number 840020
  • Investigational Site Number 840001
  • Investigational Site Number 840031
  • Investigational Site Number 840034
  • Investigational Site Number 840042
  • Investigational Site Number 840010
  • Investigational Site Number 840009
  • Investigational Site Number 840021
  • Investigational Site Number 840023
  • Investigational Site Number 840005
  • Investigational Site Number 840008
  • Investigational Site Number 840035
  • Investigational Site Number 840054
  • Investigational Site Number 840033
  • Investigational Site Number 032004
  • Investigational Site Number 032003
  • Investigational Site Number 032008
  • Investigational Site Number 032010
  • Investigational Site Number 032001
  • Investigational Site Number 032002
  • Investigational Site Number 032005
  • Investigational Site Number 032006
  • Investigational Site Number 032007
  • Investigational Site Number 032012
  • Investigational Site Number 032009
  • Investigational Site Number 036004
  • Investigational Site Number 036002
  • Investigational Site Number 036005
  • Investigational Site Number 036001
  • Investigational Site Number 036008
  • Investigational Site Number 036003
  • Investigational Site Number 036009
  • Investigational Site Number 036006
  • Investigational Site Number 152007
  • Investigational Site Number 152011
  • Investigational Site Number 152001
  • Investigational Site Number 152002
  • Investigational Site Number 152014
  • Investigational Site Number 152003
  • Investigational Site Number 152005
  • Investigational Site Number 152012
  • Investigational Site Number 152013
  • Investigational Site Number 152008
  • Investigational Site Number 152006
  • Investigational Site Number 250009
  • Investigational Site Number 250004
  • Investigational Site Number 250010
  • Investigational Site Number 250006
  • Investigational Site Number 250001
  • Investigational Site Number 250002
  • Investigational Site Number 250005
  • Investigational Site Number 250007
  • Investigational Site Number 250003
  • Investigational Site Number 250008
  • Investigational Site Number 250011
  • Investigational Site Number 380010
  • Investigational Site Number 380009
  • Investigational Site Number 380004
  • Investigational Site Number 380002
  • Investigational Site Number 380008
  • Investigational Site Number 380003
  • Investigational Site Number 380007
  • Investigational Site Number 380001
  • Investigational Site Number 380005
  • Investigational Site Number 380006
  • Investigational Site Number 392009
  • Investigational Site Number 392037
  • Investigational Site Number 392002
  • Investigational Site Number 392007
  • Investigational Site Number 392012
  • Investigational Site Number 392017
  • Investigational Site Number 392021
  • Investigational Site Number 392030
  • Investigational Site Number 392004
  • Investigational Site Number 392032
  • Investigational Site Number 392013
  • Investigational Site Number 392042
  • Investigational Site Number 392026
  • Investigational Site Number 392023
  • Investigational Site Number 392001
  • Investigational Site Number 392022
  • Investigational Site Number 392025
  • Investigational Site Number 392040
  • Investigational Site Number 392044
  • Investigational Site Number 392010
  • Investigational Site Number 392036
  • Investigational Site Number 392041
  • Investigational Site Number 392020
  • Investigational Site Number 392015
  • Investigational Site Number 392005
  • Investigational Site Number 392043
  • Investigational Site Number 392019
  • Investigational Site Number 392024
  • Investigational Site Number 392011
  • Investigational Site Number 392008
  • Investigational Site Number 392034
  • Investigational Site Number 392038
  • Investigational Site Number 392028
  • Investigational Site Number 392006
  • Investigational Site Number 392003
  • Investigational Site Number 392029
  • Investigational Site Number 392018
  • Investigational Site Number 392045
  • Investigational Site Number 392014
  • Investigational Site Number 392035
  • Investigational Site Number 410002
  • Investigational Site Number 410003
  • Investigational Site Number 410004
  • Investigational Site Number 410005
  • Investigational Site Number 410001
  • Investigational Site Number 484006
  • Investigational Site Number 484005
  • Investigational Site Number 484001
  • Investigational Site Number 484004
  • Investigational Site Number 484003
  • Investigational Site Number 554001
  • Investigational Site Number 554002
  • Investigational Site Number 616006
  • Investigational Site Number 616004
  • Investigational Site Number 616003
  • Investigational Site Number 616007
  • Investigational Site Number 616001
  • Investigational Site Number 616005
  • Investigational Site Number 616008
  • Investigational Site Number 643003
  • Investigational Site Number 643002
  • Investigational Site Number 643007
  • Investigational Site Number 643012
  • Investigational Site Number 643001
  • Investigational Site Number 643006
  • Investigational Site Number 643010
  • Investigational Site Number 643011
  • Investigational Site Number 643009
  • Investigational Site Number 643008
  • Investigational Site Number 710001
  • Investigational Site Number 710002
  • Investigational Site Number 724005
  • Investigational Site Number 724002
  • Investigational Site Number 724001
  • Investigational Site Number 724004
  • Investigational Site Number 724006
  • Investigational Site Number 724003
  • Investigational Site Number 724007
  • Investigational Site Number 792011
  • Investigational Site Number 792002
  • Investigational Site Number 792008
  • Investigational Site Number 792007
  • Investigational Site Number 792001
  • Investigational Site Number 792004
  • Investigational Site Number 792003
  • Investigational Site Number 792005
  • Investigational Site Number 792013
  • Investigational Site Number 792006
  • Investigational Site Number 804016
  • Investigational Site Number 804001
  • Investigational Site Number 804004
  • Investigational Site Number 804003
  • Investigational Site Number 804008
  • Investigational Site Number 804018
  • Investigational Site Number 804020
  • Investigational Site Number 804006
  • Investigational Site Number 804002
  • Investigational Site Number 804019
  • Investigational Site Number 804015
  • Investigational Site Number 804012

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Dupilumab 300 mg q2w

Dupilumab 200 mg q2w

Dupilumab 300 mg q4w

Dupilumab 200 mg q4w

Placebo q2w

Arm Description

2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1), followed by a single 300 mg injection q2w from Week 2 to Week 22 added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.

2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1), followed by a single 200 mg injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.

2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 300 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.

2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 200 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.

2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 (Week 1) followed by a single injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.

Outcomes

Primary Outcome Measures

Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 12: High Eosinophils -Intent to Treat (HEos-ITT) Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Absolute Change From Baseline in FEV1 at Week 12: ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Secondary Outcome Measures

Percent Change From Baseline in FEV1 at Week 12: HEos-ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Percent Change From Baseline in FEV1 at Week 12: ITT Population
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Annualized Event Rate of Severe Exacerbation During The Treatment Period: HEos-ITT Population
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Annualized Event Rate of Severe Exacerbation During The Treatment Period: ITT Population
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Time to First Severe Exacerbation: Kaplan-Meier Estimates at Week 12 and 24: HEos-ITT Population
The time to first severe exacerbation was defined as the time from the date of first dose to the date of the first severe exacerbation event. For participants who had no severe exacerbation on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first severe exacerbation was not estimated because the number of severe exacerbations was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of severe exacerbation at Week 12 and 24, are presented as the descriptive measure statistics.
Time to First Severe Exacerbation: Kaplan-Meier Estimates at Week 12 and 24: ITT Population
The time to first severe exacerbation was defined as the time from the date of first dose to the date of the first severe exacerbation event. For participants who had no severe exacerbation on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first severe exacerbation was not estimated because the number of severe exacerbations was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of severe exacerbation at Week 12 and 24, are presented as the descriptive measure statistics.
Annualized Event Rate of Loss of Asthma Control (LOAC) During The Treatment Period: HEos-ITT Population
LOAC was defined as any of the following: >=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in inhaled corticosteroid (ICS) >=4 times the dose at randomization; use of systemic corticosteroids for >=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.
Annualized Event Rate of LOAC During The Treatment Period: ITT Population
LOAC was defined as any of the following: >=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS >=4 times the dose at randomization; use of systemic corticosteroids for >=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.
Time to First LOAC Event: Kaplan-Meier Estimates at Week 12 and Week 24: HEos-ITT Population
The time to first LOAC event was defined as the time from the date of first dose to the date of the first LOAC event. For participants who had no LOAC event on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first LOAC was not estimated because the number of LOAC was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of LOAC at Week 12 and 24, are presented as the descriptive measure statistics.
Time to First LOAC Event: Kaplan-Meier Estimates at Week 12 and Week 24: ITT Population
The time to first LOAC event was defined as the time from the date of first dose to the date of the first LOAC event. For participants who had no LOAC event on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first LOAC was not estimated because the number of LOAC was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of LOAC at Week 12 and 24, are presented as the descriptive measure statistics.
Change From Baseline in Morning Asthma Symptom Score at Week 12: HEos-ITT Population
Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night-time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
Change From Baseline in Morning Asthma Symptom Score at Week 12: ITT Population
Morning asthma symptom score was determined using AM symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night-time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
Change From Baseline in Evening Asthma Symptom Score at Week 12: HEos-ITT Population
Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
Change From Baseline in Evening Asthma Symptom Score at Week 12: ITT Population
Evening asthma symptom score was determined using PM symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 12: HEos-ITT Population
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Change From Baseline in ACQ-5 Score at Week 12: ITT Population
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Score at Week 12: HEos-ITT Population
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point Likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Change From Baseline in AQLQ Global Score at Week 12: ITT Population
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point Likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol at Week 12: HEos-ITT Population
Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded by the participants in their electronic diary.
Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol at Week 12: ITT Population
Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded by the participants in their electronic diary.

Full Information

First Posted
May 10, 2013
Last Updated
June 7, 2017
Sponsor
Sanofi
Collaborators
Regeneron Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01854047
Brief Title
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
June 2013 (undefined)
Primary Completion Date
November 2014 (Actual)
Study Completion Date
April 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi
Collaborators
Regeneron Pharmaceuticals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma. Secondary Objective: To evaluate different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma, with regard to: Safety and tolerability Dupilumab systemic exposure and anti-drug antibodies
Detailed Description
Total duration per participant of approximately 43 weeks including a screening period (14-21 days), a randomized treatment period (24 weeks), and a post-treatment period (16 weeks).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
776 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dupilumab 300 mg q2w
Arm Type
Experimental
Arm Description
2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1), followed by a single 300 mg injection q2w from Week 2 to Week 22 added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
Arm Title
Dupilumab 200 mg q2w
Arm Type
Experimental
Arm Description
2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1), followed by a single 200 mg injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
Arm Title
Dupilumab 300 mg q4w
Arm Type
Experimental
Arm Description
2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 300 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
Arm Title
Dupilumab 200 mg q4w
Arm Type
Experimental
Arm Description
2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 200 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
Arm Title
Placebo q2w
Arm Type
Placebo Comparator
Arm Description
2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 (Week 1) followed by a single injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
Intervention Type
Drug
Intervention Name(s)
Dupilumab
Other Intervention Name(s)
SAR231893, REGN668
Intervention Description
Solution for injection, Subcutaneous injection
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Solution for injection, Subcutaneous injection
Intervention Type
Drug
Intervention Name(s)
ICS/LABA therapy
Intervention Description
Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
Intervention Type
Drug
Intervention Name(s)
Salbutamol/albuterol
Intervention Description
Oral inhalation as needed
Intervention Type
Drug
Intervention Name(s)
Levosalbutamol/levalbuterol
Intervention Description
Oral inhalation as needed
Primary Outcome Measure Information:
Title
Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 12: High Eosinophils -Intent to Treat (HEos-ITT) Population
Description
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time Frame
Baseline, Week 12
Title
Absolute Change From Baseline in FEV1 at Week 12: ITT Population
Description
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time Frame
Baseline, Week 12
Secondary Outcome Measure Information:
Title
Percent Change From Baseline in FEV1 at Week 12: HEos-ITT Population
Description
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time Frame
Baseline, Week 12
Title
Percent Change From Baseline in FEV1 at Week 12: ITT Population
Description
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.
Time Frame
Baseline, Week 12
Title
Annualized Event Rate of Severe Exacerbation During The Treatment Period: HEos-ITT Population
Description
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Time Frame
Baseline to Week 24
Title
Annualized Event Rate of Severe Exacerbation During The Treatment Period: ITT Population
Description
A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for >=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.
Time Frame
Baseline to Week 24
Title
Time to First Severe Exacerbation: Kaplan-Meier Estimates at Week 12 and 24: HEos-ITT Population
Description
The time to first severe exacerbation was defined as the time from the date of first dose to the date of the first severe exacerbation event. For participants who had no severe exacerbation on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first severe exacerbation was not estimated because the number of severe exacerbations was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of severe exacerbation at Week 12 and 24, are presented as the descriptive measure statistics.
Time Frame
Baseline up to Week 24
Title
Time to First Severe Exacerbation: Kaplan-Meier Estimates at Week 12 and 24: ITT Population
Description
The time to first severe exacerbation was defined as the time from the date of first dose to the date of the first severe exacerbation event. For participants who had no severe exacerbation on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first severe exacerbation was not estimated because the number of severe exacerbations was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of severe exacerbation at Week 12 and 24, are presented as the descriptive measure statistics.
Time Frame
Baseline up to Week 24
Title
Annualized Event Rate of Loss of Asthma Control (LOAC) During The Treatment Period: HEos-ITT Population
Description
LOAC was defined as any of the following: >=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in inhaled corticosteroid (ICS) >=4 times the dose at randomization; use of systemic corticosteroids for >=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.
Time Frame
Baseline to Week 24
Title
Annualized Event Rate of LOAC During The Treatment Period: ITT Population
Description
LOAC was defined as any of the following: >=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS >=4 times the dose at randomization; use of systemic corticosteroids for >=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.
Time Frame
Baseline to Week 24
Title
Time to First LOAC Event: Kaplan-Meier Estimates at Week 12 and Week 24: HEos-ITT Population
Description
The time to first LOAC event was defined as the time from the date of first dose to the date of the first LOAC event. For participants who had no LOAC event on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first LOAC was not estimated because the number of LOAC was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of LOAC at Week 12 and 24, are presented as the descriptive measure statistics.
Time Frame
Baseline up to Week 24
Title
Time to First LOAC Event: Kaplan-Meier Estimates at Week 12 and Week 24: ITT Population
Description
The time to first LOAC event was defined as the time from the date of first dose to the date of the first LOAC event. For participants who had no LOAC event on or before last dose date + 14 days, it was censored at the date of last dose date + 14 days. The median time to first LOAC was not estimated because the number of LOAC was too low in the Dupilumab arms. Therefore, alternative Kaplan-Meier statistics, the probability of LOAC at Week 12 and 24, are presented as the descriptive measure statistics.
Time Frame
Baseline up to Week 24
Title
Change From Baseline in Morning Asthma Symptom Score at Week 12: HEos-ITT Population
Description
Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night-time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
Time Frame
Baseline, Week 12
Title
Change From Baseline in Morning Asthma Symptom Score at Week 12: ITT Population
Description
Morning asthma symptom score was determined using AM symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0 = No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night-time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.
Time Frame
Baseline, Week 12
Title
Change From Baseline in Evening Asthma Symptom Score at Week 12: HEos-ITT Population
Description
Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
Time Frame
Baseline, Week 12
Title
Change From Baseline in Evening Asthma Symptom Score at Week 12: ITT Population
Description
Evening asthma symptom score was determined using PM symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.
Time Frame
Baseline, Week 12
Title
Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 12: HEos-ITT Population
Description
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Time Frame
Baseline, Week 12
Title
Change From Baseline in ACQ-5 Score at Week 12: ITT Population
Description
The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.
Time Frame
Baseline, Week 12
Title
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Score at Week 12: HEos-ITT Population
Description
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point Likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Time Frame
Baseline, Week 12
Title
Change From Baseline in AQLQ Global Score at Week 12: ITT Population
Description
The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point Likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.
Time Frame
Baseline, Week 12
Title
Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol at Week 12: HEos-ITT Population
Description
Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded by the participants in their electronic diary.
Time Frame
Baseline, Week 12
Title
Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol at Week 12: ITT Population
Description
Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded by the participants in their electronic diary.
Time Frame
Baseline, Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Participants with a physician diagnosis of moderate to severe, uncontrolled asthma for >=12 months, based on the Global Initiative for Asthma (GINA) 2009 Guidelines and: Existing treatment with moderate or high-dose inhaled corticosteroid / long-acting beta-2 agonist Forced expiratory volume (FEV1) 40 to 80% of predicted normal Asthma Control Questionnaire, 5-question version (ACQ-5) score >=1.5 Reversibility of at least 12% and 200 mL in forced expiratory volume (FEV1) Had experienced, within prior year: hospitalization, emergency or urgent care visit or systemic corticosteroid treatment for worsening asthma Exclusion criteria: Participants <18 years Chronic obstructive pulmonary disease (COPD) or other lung diseases (eg, emphysema, idiopathic pulmonary fibrosis, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis) which impaired pulmonary function tests Chest X-ray within 12 months of screening visit or at screening visit with clinically significant findings of lung disease(s) other than asthma Current smoker or cessation of smoking within 6 months prior to Visit 1 Previous smoker with a smoking history >10 pack-years The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Investigational Site Number 840050
City
Fullerton
State/Province
California
ZIP/Postal Code
92835
Country
United States
Facility Name
Investigational Site Number 840041
City
Huntington Beach
State/Province
California
ZIP/Postal Code
92647
Country
United States
Facility Name
Investigational Site Number 840019
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Facility Name
Investigational Site Number 840029
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Facility Name
Investigational Site Number 840022
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Investigational Site Number 840013
City
Mission Viejo
State/Province
California
ZIP/Postal Code
92691
Country
United States
Facility Name
Investigational Site Number 840044
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Facility Name
Investigational Site Number 840007
City
Riverside
State/Province
California
ZIP/Postal Code
92506
Country
United States
Facility Name
Investigational Site Number 840014
City
Rolling Hills Estates
State/Province
California
ZIP/Postal Code
90274
Country
United States
Facility Name
Investigational Site Number 840036
City
San Jose
State/Province
California
ZIP/Postal Code
95117
Country
United States
Facility Name
Investigational Site Number 840032
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80907
Country
United States
Facility Name
Investigational Site Number 840040
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80907
Country
United States
Facility Name
Investigational Site Number 840043
City
Denver
State/Province
Colorado
ZIP/Postal Code
80206
Country
United States
Facility Name
Investigational Site Number 840006
City
Denver
State/Province
Colorado
ZIP/Postal Code
80230
Country
United States
Facility Name
Investigational Site Number 840024
City
Denver
State/Province
Colorado
ZIP/Postal Code
80230
Country
United States
Facility Name
Investigational Site Number 840027
City
Daytona Beach
State/Province
Florida
ZIP/Postal Code
32117
Country
United States
Facility Name
Investigational Site Number 840039
City
Miami
State/Province
Florida
ZIP/Postal Code
33135
Country
United States
Facility Name
Investigational Site Number 840048
City
Albany
State/Province
Georgia
ZIP/Postal Code
31707
Country
United States
Facility Name
Investigational Site Number 840026
City
River Forest
State/Province
Illinois
ZIP/Postal Code
60305
Country
United States
Facility Name
Investigational Site Number 840053
City
Evansville
State/Province
Indiana
ZIP/Postal Code
47713
Country
United States
Facility Name
Investigational Site Number 840017
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40223-5440
Country
United States
Facility Name
Investigational Site Number 840030
City
Owensboro
State/Province
Kentucky
ZIP/Postal Code
42303
Country
United States
Facility Name
Investigational Site Number 840028
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Facility Name
Investigational Site Number 840052
City
Wheaton
State/Province
Maryland
ZIP/Postal Code
20902
Country
United States
Facility Name
Investigational Site Number 840045
City
North Dartmouth
State/Province
Massachusetts
ZIP/Postal Code
02747
Country
United States
Facility Name
Investigational Site Number 840046
City
Novi
State/Province
Michigan
ZIP/Postal Code
48375
Country
United States
Facility Name
Investigational Site Number 840051
City
Novi
State/Province
Michigan
ZIP/Postal Code
48375
Country
United States
Facility Name
Investigational Site Number 840018
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55402
Country
United States
Facility Name
Investigational Site Number 840002
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Investigational Site Number 840003
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Facility Name
Investigational Site Number 840037
City
Missoula
State/Province
Montana
ZIP/Postal Code
59804
Country
United States
Facility Name
Investigational Site Number 840004
City
Papillion
State/Province
Nebraska
ZIP/Postal Code
27103
Country
United States
Facility Name
Investigational Site Number 840011
City
Princeton
State/Province
New Jersey
ZIP/Postal Code
08540
Country
United States
Facility Name
Investigational Site Number 840016
City
Rochester
State/Province
New York
ZIP/Postal Code
14618
Country
United States
Facility Name
Investigational Site Number 840025
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45231
Country
United States
Facility Name
Investigational Site Number 840015
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45236
Country
United States
Facility Name
Investigational Site Number 840020
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45241
Country
United States
Facility Name
Investigational Site Number 840001
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73120
Country
United States
Facility Name
Investigational Site Number 840031
City
Lake Oswego
State/Province
Oregon
ZIP/Postal Code
97035
Country
United States
Facility Name
Investigational Site Number 840034
City
Medford
State/Province
Oregon
ZIP/Postal Code
97504
Country
United States
Facility Name
Investigational Site Number 840042
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Investigational Site Number 840010
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Investigational Site Number 840009
City
Upland
State/Province
Pennsylvania
ZIP/Postal Code
19013
Country
United States
Facility Name
Investigational Site Number 840021
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29303
Country
United States
Facility Name
Investigational Site Number 840023
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Investigational Site Number 840005
City
El Paso
State/Province
Texas
ZIP/Postal Code
79902
Country
United States
Facility Name
Investigational Site Number 840008
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Investigational Site Number 840035
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23225
Country
United States
Facility Name
Investigational Site Number 840054
City
Everett
State/Province
Washington
ZIP/Postal Code
98203
Country
United States
Facility Name
Investigational Site Number 840033
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Facility Name
Investigational Site Number 032004
City
Buenos Aires
ZIP/Postal Code
B6500BWQ
Country
Argentina
Facility Name
Investigational Site Number 032003
City
Buenos Aires
ZIP/Postal Code
C1121ABE
Country
Argentina
Facility Name
Investigational Site Number 032008
City
Caba
ZIP/Postal Code
1424
Country
Argentina
Facility Name
Investigational Site Number 032010
City
Caba
ZIP/Postal Code
1425
Country
Argentina
Facility Name
Investigational Site Number 032001
City
Caba
Country
Argentina
Facility Name
Investigational Site Number 032002
City
La Plata
ZIP/Postal Code
1900
Country
Argentina
Facility Name
Investigational Site Number 032005
City
Rosario
ZIP/Postal Code
2000
Country
Argentina
Facility Name
Investigational Site Number 032006
City
Rosario
ZIP/Postal Code
2000
Country
Argentina
Facility Name
Investigational Site Number 032007
City
Rosario
ZIP/Postal Code
2000
Country
Argentina
Facility Name
Investigational Site Number 032012
City
Santa Fe
ZIP/Postal Code
3000
Country
Argentina
Facility Name
Investigational Site Number 032009
City
Tucumán
ZIP/Postal Code
4000
Country
Argentina
Facility Name
Investigational Site Number 036004
City
Adelaide
ZIP/Postal Code
5000
Country
Australia
Facility Name
Investigational Site Number 036002
City
Brisbane
ZIP/Postal Code
4101
Country
Australia
Facility Name
Investigational Site Number 036005
City
Campbelltown
ZIP/Postal Code
2560
Country
Australia
Facility Name
Investigational Site Number 036001
City
Clayton
ZIP/Postal Code
3168
Country
Australia
Facility Name
Investigational Site Number 036008
City
Frankston
ZIP/Postal Code
3199
Country
Australia
Facility Name
Investigational Site Number 036003
City
Nedlands
ZIP/Postal Code
6009
Country
Australia
Facility Name
Investigational Site Number 036009
City
Prahran
ZIP/Postal Code
3004
Country
Australia
Facility Name
Investigational Site Number 036006
City
Woolloongabba
ZIP/Postal Code
4102
Country
Australia
Facility Name
Investigational Site Number 152007
City
Quillota
ZIP/Postal Code
226000
Country
Chile
Facility Name
Investigational Site Number 152011
City
Santiago
ZIP/Postal Code
00000
Country
Chile
Facility Name
Investigational Site Number 152001
City
Santiago
ZIP/Postal Code
7500710
Country
Chile
Facility Name
Investigational Site Number 152002
City
Santiago
ZIP/Postal Code
8380456
Country
Chile
Facility Name
Investigational Site Number 152014
City
Santiago
ZIP/Postal Code
8910131
Country
Chile
Facility Name
Investigational Site Number 152003
City
Santiago
Country
Chile
Facility Name
Investigational Site Number 152005
City
Santiago
Country
Chile
Facility Name
Investigational Site Number 152012
City
Santiago
Country
Chile
Facility Name
Investigational Site Number 152013
City
Santiago
Country
Chile
Facility Name
Investigational Site Number 152008
City
Talca
Country
Chile
Facility Name
Investigational Site Number 152006
City
Viña Del Mar
Country
Chile
Facility Name
Investigational Site Number 250009
City
Brest Cedex
ZIP/Postal Code
29610
Country
France
Facility Name
Investigational Site Number 250004
City
Grenoble Cedex 09
ZIP/Postal Code
38043
Country
France
Facility Name
Investigational Site Number 250010
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Investigational Site Number 250006
City
Lyon
ZIP/Postal Code
69317
Country
France
Facility Name
Investigational Site Number 250001
City
Marseille
ZIP/Postal Code
13915
Country
France
Facility Name
Investigational Site Number 250002
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Name
Investigational Site Number 250005
City
Nantes
ZIP/Postal Code
44093
Country
France
Facility Name
Investigational Site Number 250007
City
Nimes
ZIP/Postal Code
30029
Country
France
Facility Name
Investigational Site Number 250003
City
Pessac
ZIP/Postal Code
33604
Country
France
Facility Name
Investigational Site Number 250008
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Facility Name
Investigational Site Number 250011
City
Vernon
ZIP/Postal Code
27200
Country
France
Facility Name
Investigational Site Number 380010
City
Ancona
ZIP/Postal Code
60126
Country
Italy
Facility Name
Investigational Site Number 380009
City
Catania
ZIP/Postal Code
95123
Country
Italy
Facility Name
Investigational Site Number 380004
City
Ferrara
ZIP/Postal Code
44121
Country
Italy
Facility Name
Investigational Site Number 380002
City
Firenze
ZIP/Postal Code
50134
Country
Italy
Facility Name
Investigational Site Number 380008
City
Foggia
ZIP/Postal Code
71100
Country
Italy
Facility Name
Investigational Site Number 380003
City
Modena
ZIP/Postal Code
41124
Country
Italy
Facility Name
Investigational Site Number 380007
City
Padova
ZIP/Postal Code
35128
Country
Italy
Facility Name
Investigational Site Number 380001
City
Pisa
ZIP/Postal Code
56100
Country
Italy
Facility Name
Investigational Site Number 380005
City
Torino
ZIP/Postal Code
10126
Country
Italy
Facility Name
Investigational Site Number 380006
City
Verona
ZIP/Postal Code
37126
Country
Italy
Facility Name
Investigational Site Number 392009
City
Asahi-Shi
Country
Japan
Facility Name
Investigational Site Number 392037
City
Chiyoda-Ku
Country
Japan
Facility Name
Investigational Site Number 392002
City
Chuo-Ku
Country
Japan
Facility Name
Investigational Site Number 392007
City
Chuoh-Ku
Country
Japan
Facility Name
Investigational Site Number 392012
City
Edogawa-Ku
Country
Japan
Facility Name
Investigational Site Number 392017
City
Fukuoka-Shi
Country
Japan
Facility Name
Investigational Site Number 392021
City
Fukuyama-Shi
Country
Japan
Facility Name
Investigational Site Number 392030
City
Habikino-Shi
Country
Japan
Facility Name
Investigational Site Number 392004
City
Himeji-Shi
Country
Japan
Facility Name
Investigational Site Number 392032
City
Hirakata-Shi
Country
Japan
Facility Name
Investigational Site Number 392013
City
Iizuka-Shi
Country
Japan
Facility Name
Investigational Site Number 392042
City
Isesaki-Shi
Country
Japan
Facility Name
Investigational Site Number 392026
City
Itabashi-Ku
Country
Japan
Facility Name
Investigational Site Number 392023
City
Kanazawa-Shi
Country
Japan
Facility Name
Investigational Site Number 392001
City
Kitakyushu-Shi
Country
Japan
Facility Name
Investigational Site Number 392022
City
Kiyose-Shi
Country
Japan
Facility Name
Investigational Site Number 392025
City
Kobe-Shi
Country
Japan
Facility Name
Investigational Site Number 392040
City
Kodaira-Shi
Country
Japan
Facility Name
Investigational Site Number 392044
City
Kokubunji-Shi
Country
Japan
Facility Name
Investigational Site Number 392010
City
Kurashiki-Shi
Country
Japan
Facility Name
Investigational Site Number 392036
City
Kyoto-Shi
Country
Japan
Facility Name
Investigational Site Number 392041
City
Nagaoka-Shi
Country
Japan
Facility Name
Investigational Site Number 392020
City
Naka-Gun
Country
Japan
Facility Name
Investigational Site Number 392015
City
Nakano-Ku
Country
Japan
Facility Name
Investigational Site Number 392005
City
Naruto-Shi
Country
Japan
Facility Name
Investigational Site Number 392043
City
Ohta-Shi
Country
Japan
Facility Name
Investigational Site Number 392019
City
Sagamihara-Shi
Country
Japan
Facility Name
Investigational Site Number 392024
City
Sakai-Shi
Country
Japan
Facility Name
Investigational Site Number 392011
City
Sakaide-Shi
Country
Japan
Facility Name
Investigational Site Number 392008
City
Sapporo-Shi
Country
Japan
Facility Name
Investigational Site Number 392034
City
Sapporo-Shi
Country
Japan
Facility Name
Investigational Site Number 392038
City
Setagaya-Ku
Country
Japan
Facility Name
Investigational Site Number 392028
City
Sumida-Ku
Country
Japan
Facility Name
Investigational Site Number 392006
City
Tomakomai-Shi
Country
Japan
Facility Name
Investigational Site Number 392003
City
Toride-Shi
Country
Japan
Facility Name
Investigational Site Number 392029
City
Tsu-Shi
Country
Japan
Facility Name
Investigational Site Number 392018
City
Tsukubo-Gun
Country
Japan
Facility Name
Investigational Site Number 392045
City
Uruma-Shi
Country
Japan
Facility Name
Investigational Site Number 392014
City
Yokohama-Shi
Country
Japan
Facility Name
Investigational Site Number 392035
City
Yokohama-Shi
Country
Japan
Facility Name
Investigational Site Number 410002
City
Bucheon
ZIP/Postal Code
420-767
Country
Korea, Republic of
Facility Name
Investigational Site Number 410003
City
Cheongju
ZIP/Postal Code
361-711
Country
Korea, Republic of
Facility Name
Investigational Site Number 410004
City
Seoul
ZIP/Postal Code
120-752
Country
Korea, Republic of
Facility Name
Investigational Site Number 410005
City
Seoul
ZIP/Postal Code
138-736
Country
Korea, Republic of
Facility Name
Investigational Site Number 410001
City
Suwon
ZIP/Postal Code
443-721
Country
Korea, Republic of
Facility Name
Investigational Site Number 484006
City
Chihuahua
ZIP/Postal Code
31000
Country
Mexico
Facility Name
Investigational Site Number 484005
City
Distrito Federal
ZIP/Postal Code
07760
Country
Mexico
Facility Name
Investigational Site Number 484001
City
Guadalajara
ZIP/Postal Code
44100
Country
Mexico
Facility Name
Investigational Site Number 484004
City
Mexico City
ZIP/Postal Code
64718
Country
Mexico
Facility Name
Investigational Site Number 484003
City
Monterrey
ZIP/Postal Code
64460
Country
Mexico
Facility Name
Investigational Site Number 554001
City
Dunedin
ZIP/Postal Code
9012
Country
New Zealand
Facility Name
Investigational Site Number 554002
City
Wellington
ZIP/Postal Code
6021
Country
New Zealand
Facility Name
Investigational Site Number 616006
City
Bialystok
ZIP/Postal Code
15-025
Country
Poland
Facility Name
Investigational Site Number 616004
City
Gdansk
ZIP/Postal Code
80-405
Country
Poland
Facility Name
Investigational Site Number 616003
City
Gdansk
ZIP/Postal Code
80-952
Country
Poland
Facility Name
Investigational Site Number 616007
City
Krakow
ZIP/Postal Code
31-159
Country
Poland
Facility Name
Investigational Site Number 616001
City
Lodz
ZIP/Postal Code
90-153
Country
Poland
Facility Name
Investigational Site Number 616005
City
Lodz
ZIP/Postal Code
90-153
Country
Poland
Facility Name
Investigational Site Number 616008
City
Warszawa
ZIP/Postal Code
00-013
Country
Poland
Facility Name
Investigational Site Number 643003
City
Moscow
ZIP/Postal Code
105229
Country
Russian Federation
Facility Name
Investigational Site Number 643002
City
Moscow
ZIP/Postal Code
109240
Country
Russian Federation
Facility Name
Investigational Site Number 643007
City
Moscow
ZIP/Postal Code
115446
Country
Russian Federation
Facility Name
Investigational Site Number 643012
City
Moscow
ZIP/Postal Code
123182
Country
Russian Federation
Facility Name
Investigational Site Number 643001
City
Moscow
ZIP/Postal Code
125367
Country
Russian Federation
Facility Name
Investigational Site Number 643006
City
Novosibirsk
ZIP/Postal Code
630091
Country
Russian Federation
Facility Name
Investigational Site Number 643010
City
Saint-Petersburg
ZIP/Postal Code
194354
Country
Russian Federation
Facility Name
Investigational Site Number 643011
City
Saint-Petersburg
ZIP/Postal Code
196356
Country
Russian Federation
Facility Name
Investigational Site Number 643009
City
St-Petersburg
ZIP/Postal Code
197022
Country
Russian Federation
Facility Name
Investigational Site Number 643008
City
Yaroslavl
ZIP/Postal Code
150003
Country
Russian Federation
Facility Name
Investigational Site Number 710001
City
Cape Town
ZIP/Postal Code
7531
Country
South Africa
Facility Name
Investigational Site Number 710002
City
Cape Town
ZIP/Postal Code
7764
Country
South Africa
Facility Name
Investigational Site Number 724005
City
Barcelona
ZIP/Postal Code
08025
Country
Spain
Facility Name
Investigational Site Number 724002
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Investigational Site Number 724001
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Investigational Site Number 724004
City
Cáceres
ZIP/Postal Code
10003
Country
Spain
Facility Name
Investigational Site Number 724006
City
Pozuelo De Alarcón
ZIP/Postal Code
28223
Country
Spain
Facility Name
Investigational Site Number 724003
City
Sabadell
ZIP/Postal Code
08208
Country
Spain
Facility Name
Investigational Site Number 724007
City
Sant Boi De Llobregat
ZIP/Postal Code
08830
Country
Spain
Facility Name
Investigational Site Number 792011
City
Amasya
ZIP/Postal Code
53100
Country
Turkey
Facility Name
Investigational Site Number 792002
City
Ankara
ZIP/Postal Code
06100
Country
Turkey
Facility Name
Investigational Site Number 792008
City
Bursa
ZIP/Postal Code
16059
Country
Turkey
Facility Name
Investigational Site Number 792007
City
Istanbul
ZIP/Postal Code
34020
Country
Turkey
Facility Name
Investigational Site Number 792001
City
Istanbul
ZIP/Postal Code
34098
Country
Turkey
Facility Name
Investigational Site Number 792004
City
Istanbul
ZIP/Postal Code
34098
Country
Turkey
Facility Name
Investigational Site Number 792003
City
Istanbul
ZIP/Postal Code
34844
Country
Turkey
Facility Name
Investigational Site Number 792005
City
Izmir
ZIP/Postal Code
35040
Country
Turkey
Facility Name
Investigational Site Number 792013
City
Kirikkale
ZIP/Postal Code
71450
Country
Turkey
Facility Name
Investigational Site Number 792006
City
Mersin
ZIP/Postal Code
33070
Country
Turkey
Facility Name
Investigational Site Number 804016
City
Donetsk
ZIP/Postal Code
83099
Country
Ukraine
Facility Name
Investigational Site Number 804001
City
Kharkiv
ZIP/Postal Code
61124
Country
Ukraine
Facility Name
Investigational Site Number 804004
City
Kyiv
ZIP/Postal Code
03049
Country
Ukraine
Facility Name
Investigational Site Number 804003
City
Kyiv
ZIP/Postal Code
03680
Country
Ukraine
Facility Name
Investigational Site Number 804008
City
Kyiv
ZIP/Postal Code
03680
Country
Ukraine
Facility Name
Investigational Site Number 804018
City
Kyiv
ZIP/Postal Code
03680
Country
Ukraine
Facility Name
Investigational Site Number 804020
City
Kyiv
ZIP/Postal Code
03680
Country
Ukraine
Facility Name
Investigational Site Number 804006
City
Odessa
ZIP/Postal Code
65025
Country
Ukraine
Facility Name
Investigational Site Number 804002
City
Poltava
ZIP/Postal Code
36038
Country
Ukraine
Facility Name
Investigational Site Number 804019
City
Vinnytsya
ZIP/Postal Code
21001
Country
Ukraine
Facility Name
Investigational Site Number 804015
City
Yalta
ZIP/Postal Code
98603
Country
Ukraine
Facility Name
Investigational Site Number 804012
City
Zaporozhye
ZIP/Postal Code
69118
Country
Ukraine

12. IPD Sharing Statement

Citations:
PubMed Identifier
27130691
Citation
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016 Jul 2;388(10039):31-44. doi: 10.1016/S0140-6736(16)30307-5. Epub 2016 Apr 27.
Results Reference
result
PubMed Identifier
35636689
Citation
Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, Johnson RR, Kapoor U, Khokhar FA, Daizadeh N, Chen Z, Laws E, Ortiz B, Jacob-Nara JA, Mannent LP, Rowe PJ, Deniz Y. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28.
Results Reference
derived
PubMed Identifier
33010038
Citation
Bourdin A, Papi AA, Corren J, Virchow JC, Rice MS, Deniz Y, Djandji M, Rowe P, Pavord ID. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. Allergy. 2021 Jan;76(1):269-280. doi: 10.1111/all.14611. Epub 2020 Oct 21.
Results Reference
derived
PubMed Identifier
31351189
Citation
Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, Peters AT, Pavord ID, Ford LB, Sher L, Rabe KF, Rice MS, Rowe P, Lu Y, Harel S, Jagerschmidt A, Khan AH, Kamat S, Pirozzi G, Amin N, Ruddy M, Graham NMH, Mannent LP, Teper A. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2020 Feb;8(2):527-539.e9. doi: 10.1016/j.jaip.2019.07.016. Epub 2019 Jul 24.
Results Reference
derived
PubMed Identifier
31075309
Citation
Corren J, Castro M, Ford LB, Bernstein JA, Jayawardena S, Maroni J, Rowe P, Amin N, Pirozzi G, Graham NMH, Khan A, Eckert L, Teper A. Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. Ann Allergy Asthma Immunol. 2019 Aug;123(2):222-224.e1. doi: 10.1016/j.anai.2019.04.028. Epub 2019 May 8. No abstract available.
Results Reference
derived
PubMed Identifier
30138668
Citation
Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, Graham NMH, Mastey V, Abbe A, Taniou C, Mahajan P, Teper A, Pirozzi G, Eckert L. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019 Jan;122(1):41-49.e2. doi: 10.1016/j.anai.2018.08.005. Epub 2018 Aug 21.
Results Reference
derived
PubMed Identifier
29355679
Citation
Weinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, Joish VN, Amin N, Maroni J, Rowe P, Graham NMH, Teper A. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018 Jul;142(1):171-177.e1. doi: 10.1016/j.jaci.2017.11.051. Epub 2018 Jan 31.
Results Reference
derived

Learn more about this trial

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

We'll reach out to this number within 24 hrs